Dimerix (ASX:DXB) received the first development milestone payment of 400 million yen from Fuso Pharmaceutical Industries, the exclusive licensee of product candidate DMX-200 in Japan, according to a Monday filing with the Australian bourse.
DMX-200 is being developed for the potential treatment of focal segmental glomerulosclerosis kidney disease, the filing said.
The company may receive additional potential development and regulatory milestone payments of up to 3 billion yen and sales milestone payments of up to 6.8 billion yen, according to the filing.
Shares rose nearly 2% in morning trade Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.